BEN 9160
Alternative Names: BEN-9160Latest Information Update: 16 Oct 2022
Price :
$50 *
At a glance
- Originator BenevolentAI
- Class Neuroprotectants; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis
Most Recent Events
- 27 Sep 2022 BEN 9160 is available for licensing as of 27 Sep 2022. https://www.benevolent.com/ (BenevolentAI website, September 2022)
- 27 Sep 2022 BenevolentAI files for patent protection for BEN 9160 prior to September 2022
- 27 Sep 2022 Preclinical trials in Amyotrophic lateral sclerosis in United Kingdom (PO) prior to September 2022